<img height="1" width="1" src="https://www.facebook.com/tr?id=1582471781774081&amp;ev=PageView &amp;noscript=1">
  • Menu
  • crown-logo-symbol-1-400x551

Find it Quickly

Get Started

Select the option that best describes what you are looking for

  • Services
  • Models
  • Scientific Information

Search Here For Services

Click Here to Start Over

Search Here For Models

Click Here to Start Over

Search Here For Scientific Information

Click Here to Start Over

In Vitro

Boost oncology drug discovery with XenoBase®, featuring the largest cell line selection and exclusive 3D organoid models. Benefit from OrganoidXplore™ and OmniScreen™ for rapid, in-depth analysis.

Learn More

In Vivo

Enhance drug development with our validated in vivo models, in vitro/ex vivo assays, and in silico modeling. Tailored solutions to optimize your candidates.

Learn More

Tissue

Experience ISO-certified biobanking quality. Access top biospecimens from a global clinical network, annotated by experts for precise research.

Learn More

Biomarkers and Bioanalysis

Leverage our global labs and 150+ scientists for fast, tailored project execution. Benefit from our expertise, cutting-edge tech, and validated workflows for reliable data outcomes.

Learn More

Data Science and Bioinformatics

Harness your data and discover biomarkers with our top bioinformatics expertise. Maximize data value and gain critical insights to accelerate drug discovery and elevate projects.

Learn More

KRAS

Accelerate innovative cancer treatments with our advanced models and precise drug screening for KRAS mutations, efficiently turning insights into clinical breakthroughs.

Learn More

EGFR

Advance translational pharmacology with our diverse pre-clinical models, robust assays, and data science-driven biomarker analysis, multi-omics, and spatial biology.

Learn More

Drug Resistance

Our suite integrates preclinical solutions, bioanalytical read-outs, and multi-omics to uncover drug resistance markers and expedite discovery with our unique four-step strategy.

Learn More

Patient Tissue

Enhance treatments with our human tumor and mouse models, including xenografts and organoids, for accurate cancer biology representation.

Learn More

Bioinformatics

Apply the most appropriate in silico framework to your pharmacology data or historical datasets to elevate your study design and analysis, and to improve your chances of clinical success.

Learn More

Biomarker Analysis

Integrate advanced statistics into your drug development projects to gain significant biological insight into your therapeutic candidate, with our expert team of bioinformaticians.

Learn More

CRISPR/Cas9

Accelerate your discoveries with our reliable CRISPR solutions. Our global CRISPR licenses cover an integrated drug discovery platform for in vitro and in vivo efficacy studies.

Learn More

Genomics

Rely on our experienced genomics services to deliver high quality, interpretable results using highly sensitive PCR-based, real-time PCR, and NGS technologies and advanced data analytics.

Learn More

In Vitro High Content Imaging

Gain more insights into tumor growth and disease progression by leveraging our 2D and 3D fluorescence optical imaging.

Learn More

Mass Spectrometry-based Proteomics

Next-generation ion mobility mass spectrometry (MS)-based proteomics services available globally to help meet your study needs.

Learn More

Ex Vivo Patient Tissue

Gain better insight into the phenotypic response of your therapeutic candidate in organoids and ex vivo patient tissue.

Learn More

Spatial Multi-Omics Analysis

Certified CRO services with NanoString GeoMx Digital Spatial Profiling.

Learn More

Biomarker Discovery

De-risk your drug development with early identification of candidate biomarkers and utilize our biomarker discovery services to optimize clinical trial design.

Learn More

DMPK Services

Rapidly evaluate your molecule’s pharmaceutical and safety properties with our in vivo drug metabolism and pharmacokinetic (DMPK) services to select the most robust drug formulations.

Learn More

Efficacy Testing

Explore how the novel HuGEMM™ and HuCELL™ platforms can assess the efficacy of your molecule and accelerate your immuno-oncology drug discovery programs.

Learn More

Laboratory Services

Employ cutting-edge multi-omics methods to obtain accurate and comprehensive data for optimal data-based decisions.

Learn More

Pharmacology & Bioanalytical Services

Leverage our suite of structural biology services including, recombinant protein expression and protein crystallography, and target validation services including RNAi.

Learn More

Screens

Find the most appropriate screen to accelerate your drug development: discover in vivo screens with MuScreen™ and in vitro cell line screening with OmniScreen™.

Learn More

Toxicology

Carry out safety pharmacology studies as standalone assessments or embedded within our overall toxicological profiling to assess cardiovascular, metabolic and renal/urinary systems.

Learn More

Our Company

Global CRO in California, USA offering preclinical and translational oncology platforms with high-quality in vivo, in vitro, and ex vivo models.

Learn More

Our Purpose

Learn more about the impact we make through our scientific talent, high-quality standards, and innovation.

Learn More

Our Responsibility

We build a sustainable future by supporting employee growth, fostering leadership, and exceeding customer needs. Our values focus on innovation, social responsibility, and community well-being.

Learn More

Meet Our Leadership Team

We build a sustainable future by fostering leadership, employee growth, and exceeding customer needs with innovation and social responsibility.

Learn More

Scientific Advisory Board

Our Scientific Advisory Board of experts shapes our strategy and ensures top scientific standards in research and development.

Learn More

News & Events

Stay updated with Crown Bioscience's latest news, achievements, and announcements. Check our schedule for upcoming events and plan your visit.

Learn More

Career Opportunities

Join us for a fast-paced career addressing life science needs with innovative technologies. Thrive in a respectful, growth-focused environment.

Learn More

Scientific Publications

Access our latest scientific research and peer-reviewed articles. Discover cutting-edge findings and insights driving innovation and excellence in bioscience.

Learn More

Resources

Discover valuable insights and curated materials to support your R&D efforts. Explore the latest trends, innovations, and expertly curated content in bioscience.

Learn More

Blogs

Explore our blogs for the latest insights, research breakthroughs, and industry trends. Stay educated with expert perspectives and in-depth articles driving innovation in bioscience.

Learn More

  • Platforms
  • Target Solutions
  • Technologies
  • Service Types

Finding the Right Path in Lung Cancer Therapy

Lung cancer is the biggest cancer killer worldwide, with historically low survival rates and a high number of cases caused by smoking. With targeted therapies now greatly improving treatment options, research is needed to uncover all of the mechanisms and oncogenes which are driving lung cancer forward. Newly published research has identified novel mutations that switch on major oncogenic pathways in lung cancer potentially putting scientists on the right path to new treatments and improved survival for this deadly disease.

Lung cancer is the most common cause of cancer death worldwide, accounting for more than 1 million deaths every year. This year it's estimated in the US alone that almost 160,000 people will die from lung cancer, which is over one-quarter of all US cancer deaths. Survival rates for the disease have historically been low, as patients are often diagnosed at a late stage where a cure is impossible. Recently, targeted therapies have improved treatment options for lung adenocarcinoma patients with activated oncogenes, with therapies such as gefitinib and erlotinib targeting EGFR and crizotinib targeting ALK. However, driving oncogene mutations remain to be identified for many other adenocarcinomas and other gene mutations give resistance to EGFR targeted agents, often leaving standard chemotherapy as the main treatment option.

Research published in Nature last month by The Cancer Genome Atlas Research Network is hoping to change this, by presenting the largest and most comprehensive genomic study of adenocarcinomas to date. The study analyzed samples from 230 lung adenocarcinoma patients using a wide variety of profiling techniques including messenger RNA, microRNA, DNA sequencing, and proteomic analysis. The work found mutations, fusions, chromatin modifications, and splicing alterations in the cancers, and used these to identify key pathways and potential driver oncogenes for the disease.

The main route that was identified in causing adenocarcinoma was the RTK/RAS/RAF pathway, which was initially shown to be activated or stuck on in 62% of patients with “common” pathway mutations, e.g. in KRAS, BRAF, and EGFR. The activated pathway continuously drives cancer cell proliferation, cell survival, and tumor growth. This finding is not particularly surprising, as many of the common mutations identified were already known in lung cancer, and gefitinib, erlotinib, and crizotinib already target members of the RTK/RAS/RAF pathway.

The researchers then turned their attention to patients without “common” RTK/RAS/RAF pathway mutations, to see if any previously unreported oncogenes could also be causing constitutive pathway activation. HER2 and MET amplifications, and NF1 and RIT1 mutations were found to be turning on the pathway in 14% of these patients and have now been put forward as potential driver oncogenes for these tumors. Targeting these new genes could provide novel treatment options in adenocarcinoma, and may provide alternative therapeutic routes to target the RTK/RAS/RAF pathway when resistance to initial therapies occurs. The research also highlights the importance of fully understanding tumor backgrounds and how many different mutations within the same tumor subtype can all work to activate the same oncogenic pathway.

Crown Bioscience supports research into different subtypes of lung cancer through the use of our large collection of clinically relevant Xenograft and Patient-Derived Xenograft (PDX) models available for drug discovery and translational sciences. We have the largest commercially available collection of PDX models (HuPrime®), which are well-characterized and are easily searchable through our free, online database (HuBase™) which can be used to identify relevant models to interrogate pathways, efficacy, and biomarkers. HuPrime contains a diverse collection of NSCLC PDX models with previously published “common” mutations in KRAS and EGFR which have an activated RTK/RAS/RAF pathway, and also includes models with NF1 mutations, MET amplifications, and ALK gene fusions. Our NSCLC models also have CDKN2A and STK11 mutations which were found in other activating pathways highlighted in this research, as well as FGFR gene fusions.

Contact us today at busdev@crownbio.com to discover how we can transform your adenocarcinoma and lung cancer research.


Related Posts